4.2 Article

Structure and characterization of human carboxylesterase 1A1, 1A2, and 1A3 genes

期刊

PHARMACOGENETICS AND GENOMICS
卷 18, 期 10, 页码 911-920

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/FPC.0b013e32830b0c5e

关键词

carboxylesterase 1A1; gene structure; genetic polymorphism

向作者/读者索取更多资源

Objective Human carboxylesterase (CES) 1A1 gene (14 exons) and CES1A3 pseudogene (six exons) are inverted and duplicated genes in a reference sequence (NT_010498). In contrast, earlier studies reported the CES1A2 gene (14 exons) instead of the CES1A3 pseudogene. The sequences of the CES1A2 gene downstream and upstream of intron 1 are identical with those of the CES1A1 and CES1A3 genes, respectively. A CES1A1 variant of which exon 1 is converted with that of the CES1A3 gene (the transcript is CES1A2) has recently been identified. We sought to clarify the confusing gene structure of human CES1A. Methods A panel of 55 human liver as well as 318 blood samples (104 Caucasians, 107 African-Americans, and 107 Japanese) was used to clarify the gene structures of CES1A1, CES1A2 and CES1A3. Real-time reverse transcription-PCR and western blot analysis were carried out Imidapril hydrolase activity in human liver microsomes and cytosol was determined by liquid chromatography-mass spectrometry (LC-MS)/MS. Results By PCR analyses, we found that the CES1A2 gene is a variant of the CES1A3 gene. Four haplotypes, A (CES1A1 wild type and CES1A3), B (CES1A1 wild type and CES1A2), C (CES1A1 variant and CES1A3), and D (CES1A1 variant and CES1A2), were demonstrated. Ethnic differences were observed in allele frequencies of CES1A1 variant (17.3% in Caucasians and African-Americans and 25.2% in Japanese) and CES1A2 gene (14.4% in Caucasians, 5.1% in African-Americans, and 31.3% in Japanese). In human livers whose diplotype was A/A and C/C or C/D, no CES1A2 and CES1A1 mRNA was detected, respectively. In the other participants, the CES1A1 mRNA levels were higher than the CES1A2 mRNA levels. The CES1A proteins translated from CES1A1 mRNA and CES1A2 mRNA were detected in both human liver microsomes and cytosol fractions suggesting that the differences in exon 1 encoding a signal peptide did not affect the subcellular localization. Imidapril hydrolase activities reflected the CES1A protein levels. Conclusion We found that the CES1A2 gene is a variant of the CES1A3 pseudogene. The findings presented here significantly increase our understanding about the gene structure and expression properties of human CES1A.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Biochemistry & Molecular Biology

β-adrenergic receptor inhibition enhances oncolytic herpes virus propagation through STAT3 activation in gastric cancer

Jiali Hu, Ruitao Lu, Yu Zhang, Wei Li, Qian Hu, Cuiyu Chen, Zhaoqian Liu, Wei Zhang, Ling Chen, Ran Xu, Jia Luo, Howard L. McLeod, Yijing He

Summary: The study demonstrates that propranolol pretreatment can enhance the propagation and therapeutic efficacy of T1012G virus in gastric cancer by regulating the STAT3-PKR signaling cascade, even in the presence of type I interferons.

CELL AND BIOSCIENCE (2021)

Article Genetics & Heredity

High-throughput screening and genome-wide analyses of 44 anticancer drugs in the 1000 Genomes cell lines reveals an association of the NQO1 gene with the response of multiple anticancer drugs

Farida S. Akhtari, Adrian J. Green, George W. Small, Tammy M. Havener, John S. House, Kyle R. Roell, David M. Reif, Howard L. McLeod, Timothy Wiltshire, Alison A. Motsinger-Reif

Summary: Cancer patients show a wide range of inter-individual variability in response and toxicity to anticancer drugs, largely influenced by genetic variation. By conducting a genome-wide association study, the NQO1 gene was identified to be associated with the dose-response of multiple anticancer drug treatments, including new associations with additional treatments. Baseline gene expression of NQO1 was found to be positively correlated with response for the majority of the treatments surveyed.

PLOS GENETICS (2021)

Article Pharmacology & Pharmacy

Arylacetamide deacetylase knockout mice are sensitive to ketoconazole-induced hepatotoxicity and adrenal insufficiency

Mai Nagaoka, Tatsuki Fukami, Fumiya Kisui, Takuya Yamada, Yoshiyuki Sakai, Kiyomichi Tashiro, Takuo Ogiso, Keigo Konishi, Shiori Honda, Keiya Hirosawa, Masataka Nakano, Miki Nakajima

Summary: This study demonstrated the significance of AADAC in ketoconazole-induced toxicity through experiments on Aadac knockout mice, showing that AADAC deficiency exacerbates liver injury and steroidogenesis inhibition caused by ketoconazole. The findings suggest that the hydrolysis of ketoconazole by AADAC can mitigate ketoconazole-induced toxicities.

BIOCHEMICAL PHARMACOLOGY (2022)

Article Oncology

Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients

Julia C. F. Quintanilha, Jin Wang, Alexander B. Sibley, Chen Jiang, Amy S. Etheridge, Fei Shen, Guanglong Jiang, Flora Mulkey, Jai N. Patel, Daniel L. Hertz, Elizabeth Claire Dees, Howard L. McLeod, Monica Bertagnolli, Hope Rugo, Hedy L. Kindler, William Kevin Kelly, Mark J. Ratain, Deanna L. Kroetz, Kouros Owzar, Bryan P. Schneider, Danyu Lin, Federico Innocenti

Summary: A genome-wide association study (GWAS) meta-analysis was conducted in European ancestry bevacizumab-treated patients, identifying significant SNPs associated with hypertension and proteinuria, providing new markers for predicting toxicities induced by bevacizumab.

BRITISH JOURNAL OF CANCER (2022)

Correction Oncology

Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients (Oct, 10.1038/s41416-021-01617-1, 2021)

Julia C. F. Quintanilha, Jin Wang, Alexander B. Sibley, Chen Jiang, Amy S. Etheridge, Fei Shen, Guanglong Jiang, Flora Mulkey, Jai N. Patel, Daniel L. Hertz, Elizabeth Claire Dees, Howard L. McLeod, Monica Bertagnolli, Hope Rugo, Hedy L. Kindler, William Kevin Kelly, Mark J. Ratain, Deanna L. Kroetz, Kouros Owzar, Bryan P. Schneider, Danyu Lin, Federico Innocenti

BRITISH JOURNAL OF CANCER (2022)

Article Oncology

UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients

Emma C. Hulshof, Mirjam de With, Femke M. de Man, Geert-Jan Creemers, Birgit A. L. M. Deiman, Jesse J. Swen, Saskia Houterman, Stijn L. W. Koolen, Sander Bins, Anna M. J. Thijs, Marjan M. J. Laven, Anke M. Hovels, Saskia A. C. Luelmo, Danny Houtsma, Katerina Shulman, Howard L. McLeod, Ron H. N. van Schaik, Henk-Jan Guchelaar, Ron H. J. Mathijssen, Hans Gelderblom, Maarten J. Deenen

Summary: This study aimed to determine the safety, feasibility, pharmacokinetics, and cost of UGT1A1 genotype-guided dosing of irinotecan. The results showed that UGT1A1 genotype-guided dosing significantly reduces the incidence of febrile neutropenia in UGT1A1 PM patients treated with irinotecan, results in a therapeutically effective systemic drug exposure, and is cost-saving.

EUROPEAN JOURNAL OF CANCER (2022)

Article Pharmacology & Pharmacy

Comparison of FDA Table of Pharmacogenetic Associations and Clinical Pharmacogenetics Implementation Consortium guidelines

Daryl Pritchard, Jai N. Patel, Lindsay E. Stephens, Howard L. McLeod

Summary: This report compares PGx information in the FDA Table of Pharmacogenetic Associations with CPIC guidelines and finds significant differences between the two sources, including the drugs listed and gene-drug associations. FDA and CPIC have different perspectives and criteria when evaluating PGx associations and clinical validity, leading to divergent information in their respective sources.

AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2022)

Article Genetics & Heredity

Dissecting the role of cell signaling versus CD8+ T cell modulation in propranolol antitumor activity

Wei Li, Jielin Wan, Cuiyu Chen, Chengfang Zhou, Ping Liao, Qian Hu, Jiali Hu, Yang Wang, Yu Zhang, Cong Peng, Yuanfei Huang, Weihua Huang, Wei Zhang, Howard L. Mcleod, Yijing He

Summary: Preclinical and early clinical studies have shown that propranolol, a beta-adrenergic receptor blocker, can exert antitumor activity through cell signaling and immune function pathways. The inhibition of beta(2)-AR signaling selectively suppresses cell viability and inhibits xenograft growth, while propranolol can activate CD8(+) T cells in the tumor microenvironment. However, selective beta(1) or beta(2)-AR blockers have no significant effect on the tumor immune microenvironment. Therefore, the antitumor activity of propranolol is predominantly dependent on cell signaling rather than the activation of CD8(+) T cells.

JOURNAL OF MOLECULAR MEDICINE-JMM (2022)

Article Pharmacology & Pharmacy

Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype

Roseann S. Gammal, Munir Pirmohamed, Andrew A. Somogyi, Sarah A. Morris, Christine M. Formea, Amanda L. Elchynski, Kazeem A. Oshikoya, Howard L. McLeod, Cyrine E. Haidar, Michelle Whirl-Carrillo, Teri E. Klein, Kelly E. Caudle, Mary Relling

Summary: Glucose-6-phosphate dehydrogenase (G6PD) deficiency is associated with the development of acute hemolytic anemia in the presence of oxidative stress. This guideline provides information on using G6PD genotype for diagnosing G6PD deficiency and categorizes medications based on their risk level in individuals with G6PD deficiency. High-risk medications should be avoided, medium-risk medications should be used with caution, and low-risk medications can be used without considering the G6PD phenotype.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2023)

Article Biochemistry & Molecular Biology

A two-stage genome-wide association study to identify novel genetic loci associated with acute radiotherapy toxicity in nasopharyngeal carcinoma

Yang Wang, Fan Xiao, Yi Zhao, Chen-Xue Mao, Lu-Lu Yu, Lei-Yun Wang, Qi Xiao, Rong Liu, Xi Li, Howard L. McLeod, Bi-Wen Hu, Yu-Ling Huang, Qiao-Li Lv, Xiao-Xue Xie, Wei-Hua Huang, Wei Zhang, Cheng-Xian Guo, Jin-Gao Li, Ji-Ye Yin

Summary: This study identified novel risk loci for skin toxicity and dysphagia in nasopharyngeal carcinoma patients receiving radiotherapy, including rs6711678, rs4848597, rs4848598, rs2091255, and rs584547. Prediction models integrating genetic and clinical factors were also established.

MOLECULAR CANCER (2022)

Article Andrology

Propranolol suppresses bladder cancer by manipulating intracellular pH via NHE1

Qian Hu, Jiali Hu, Cuiyu Chen, Yang Wang, Yu Zhang, Jielin Wan, Ouyang Jing, Hanying Yi, Shiyu Wang, Weihua Huang, Jie Liu, Wei Zhang, Howard L. McLeod, Ran Xu, Yijing He

Summary: The study found that propranolol can inhibit the growth of bladder cancer cells and induce apoptosis. It also inhibits bladder cancer growth in a mouse model. Propranolol also activates systemic antitumor immune response.

TRANSLATIONAL ANDROLOGY AND UROLOGY (2022)

Article Oncology

PARPi treatment enhances radiotherapy-induced ferroptosis and antitumor immune responses via the cGAS signaling pathway in colorectal cancer

Dongya Shen, Jia Luo, Ling Chen, Wenjuan Ma, Xiaoyuan Mao, Yu Zhang, Juyan Zheng, Yang Wang, Jielin Wan, Shiyu Wang, Jing Ouyang, Hanying Yi, Dongbo Liu, Weihua Huang, Wei Zhang, Zhaoqian Liu, Howard L. McLeod, Yijing He

Summary: In cancer cells, the PARP-1 and PARP2 proteins regulate DNA repair pathways to protect against therapy-induced DNA damage and cell death. Combining PARP inhibitors (PARPis) with radiotherapy has been effective in clinical trials, but the mechanisms underlying their action are still unclear. This study reveals that the activation of cyclic GMP-AMP synthase (cGAS) signaling by ionizing radiation (IR)-induced DNA damage leads to regulated cell death, known as ferroptosis, and an anti-tumor immune response. Additionally, a widely used PARPi called niraparib enhances cGAS-mediated ferroptosis and immune activation. The depletion of cGAS expression compromises IR-induced ferroptosis and reverses the infiltration of CD8(+) T cells in colorectal cancer models. High expression of cGAS, ATF3, and PTGS2, as well as a high density of CD8(+) T cells, is associated with a significantly higher disease-free survival rate in patients with rectal cancer after standard radiotherapy.

CANCER LETTERS (2022)

Article Health Care Sciences & Services

The Development of an Infrastructure to Facilitate the Use of Whole Genome Sequencing for Population Health

Nephi A. Walton, Brent Hafen, Sara Graceffo, Nykole Sutherland, Melanie Emmerson, Rachel Palmquist, Christine M. Formea, Maricel Purcell, Bret Heale, Matthew A. Brown, Christopher J. Danford, Sumathi I. Rachamadugu, Thomas N. Person, Katherine A. Shortt, G. Bryce Christensen, Jared M. Evans, Sharanya Raghunath, Christopher P. Johnson, Stacey Knight, Viet T. Le, Jeffrey L. Anderson, Margaret Van Meter, Teresa Reading, Derrick S. Haslem, Ivy C. Hansen, Betsey Batcher, Tyler Barker, Travis J. Sheffield, Bhaskara Yandava, David P. Taylor, Pallavi Ranade-Kharkar, Christopher C. Giauque, Kenneth R. Eyring, Jesse W. Breinholt, Mickey R. Miller, Payton R. Carter, Jason L. Gillman, Andrew W. Gunn, Kirk U. Knowlton, Joshua L. Bonkowsky, Kari Stefansson, Lincoln D. Nadauld, Howard L. McLeod

Summary: The clinical use of genomic analysis has rapidly expanded, leading to increased availability and utility of genomic information in clinical care. Developing an infrastructure utilizing informatics tools and clinical processes is critical in facilitating the use of whole genome sequencing data for population health management. It is important to address domain-specific challenges and scale such a system to multiple clinical domains, supported by informatics tools and complementary to existing clinical processes.

JOURNAL OF PERSONALIZED MEDICINE (2022)

Correction Pharmacology & Pharmacy

Comparison of FDA Table of Pharmacogenetic Associations and Clinical Pharmacogenetics Implementation Consortium guidelines (vol 79, pg 993, 2022)

Daryl Pritchard, Jai N. Patel, Lindsay E. Stephens, Howard L. McLeod

AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2022)

Article Health Care Sciences & Services

Budget Impact of Adaptive Abiraterone Therapy for Castration-Resistant Prostate Cancer

Neil T. Mason, Jason M. Burkett, Ryan S. Nelson, Julio M. Pow-Sang, Robert A. Gatenby, Timothy Kubal, John W. Peabody, G. Douglas Letson, Howard L. McLeod, Jingsong Zhang

Summary: Adaptive abiraterone therapy, based on mathematical modeling of tumor subpopulations, has been shown to extend time to disease progression and reduce costs compared to standard continuous abiraterone therapy in patients with metastatic CRPC. The study suggests that precision medicine strategies, like adaptive abiraterone treatment, can improve outcomes and reduce costs without the need for new drug discovery.

AMERICAN HEALTH AND DRUG BENEFITS (2021)

暂无数据